The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 329-332

  McDowell, G ^a   Coutie, W ^b   Shaw, C ^a   Buchanan, K D ^a   Struthers, A D ^b   Nicholls, D P ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

atrial natriuretic peptide; brain natriuretic peptide; candoxatril; neutral endopeptidase inhibitor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CANDOXATRIL; CAPTOPRIL; ENDOTHELIN; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEART FAILURE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031044502     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00545.x     Document Type: Article

References (13)

1. McDowell G, Shaw C, Buchanan KD, Nicholls DP. The natriuretic peptide family. Eur J Clin Invest 1995; 25: 291-298.
2. Roques BP, Noble F, Dauge V, Fournie-Zaiuski MC, Beaumont A. Neutral endopeptidase 24.11 structure, inhibition and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87-146.
3. Northridge DB, Jardine AJ, Alabaster CT, et al. Preliminary studies with a novel atriopeptidase inhibitor UK 69, 579 in animals, normal volunteers and heart failure patients. Lancet 1989; ii: 591-593.
4. Elsner P, Muntze A, Kromer EP, Riegger GAJ. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70: 494-498.
5. Motwani JG, Lang CC, Allen MJ, Johnston HF, Struthers AD. Dose-ranging effects of candoxatril on elimination of endogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther 1993; 54: 661-669.
6. Lang CC, Motwani J, Coutie WJ, Struthers AD. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet 1991; 338: 255.
7. Nugent AM, Onuoha GN, McEneaney DJ, et al. Variable patterns of atrial natriuretic peptide secretion in man. Eur J Clin Invest 1994; 24: 267-274.
8. Haynes WG, Webb DJ. The endothelin family of peptides; local hormones with diverse roles in health and disease. Clin Sci 1993; 84: 485-500.
9. Lebel N, D'Orleans-Juste P, Fournier A, Sirois P. Role of the neutral endopeptidase 24.11 in the conversion of big endothelin in guinea pig lung parenchyma. Br J Pharmacol 1996; 117: 184-188.
10. Ando SI, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on haemodynamic, sympathetic activity, heart rate variability and endothelin. Hypertension 1995; 26 [pt2] 1160-1166.
11. Ferro CJ, Haynes WG, Webb DJ. Role of neutral endopeptidase in control of peripheral vascular tone in man. Br J Clin Pharmacol 1996; 41: 440P-441P.
12. Preibizz JJ. Calcitonin gene-related peptide and regulation of human cardiovascular homeostasis. Am J Hypertension 1993; 6: 434-450.
13. Onuoha GN, Nugent AM, Steele IC, et al. Pattern of neuropeptide secretion in ischaemic heart disease. Eur J Clin Invest 1993; 23(suppl): A6.